Chiron lowers Fluvirin production estimate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron will produce 18 mil. to 20 mil. doses of its influenza vaccine Fluvirin for the 2005-06 flu season, the company says June 15. The firm previously projected its production level would be 25 mil. to 30 mil. doses (1Pharmaceutical Approvals Monthly June 2005, In Brief). Chiron expects FDA to inspect its manufacturing facility this month to determine whether deficiencies noted in a December 2004 warning letter have been resolved. GlaxoSmithKline plans to provide 10 mil. doses of its flu vaccine Fluarix for the 2005-06 season; the firm submitted the Fluarix BLA May 25...
You may also be interested in...
GSK Fluarix submission
GlaxoSmithKline anticipates an expedited review for its influenza vaccine Fluarix; the company submitted a BLA May 25. GSK has begun a manufacturing ramp-up aimed at providing 10 mil. doses of the vaccine for the 2005-06 flu season. Competitor Chiron, whose Fluvirin was removed from the market last season due to manufacturing issues, expects to begin shipping 25 mil. to 30 mil. doses of its product in the third quarter; the firm said FDA is slated to inspect its manufacturing facility in mid-June to late July...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.